$AMIX

Autonomix Medical (AMIX) will report Q2'26 earnings on November 9. Analysts expect $0 revenue and a loss of $2.62 per share. Details are available on the company's financials page.

Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under Item 5.07 of this Current Report, on October 29, 2026, Autonomix Medical, Inc. (the “Company”) hel

Autonomix Medical Inc. (AMIX) received a Canadian patent for its catheter-based nerve therapy technology. The patent covers tools for accessing tissue and nerves through a lumen wall, with multi-site sensing and real-time feedback capabilities. The company now has 112 issued or pending patents worldwide, with expirations extending into the late 2030s. The technology is investigational and not yet cleared for marketing in the U.S.

Autonomix Medical (AMIX) received a Canadian patent for its catheter-based transvascular intervention technology, expanding its IP portfolio to 112 issued or pending patents. The patent covers tools for accessing tissue beyond vessel walls, real-time procedural validation, and adaptive treatment delivery. The company aims to advance nerve-targeted therapies across multiple clinical applications, with patents also issued in the U.S. and Europe.

Autonomix Medical (AMIX) reported positive FDA feedback supporting a Class II regulatory pathway for its standalone sensing platform, aiming for U.S. clearance in about 15 months. The FDA's guidance suggests substantial equivalence to a previously cleared device. The company plans to establish a regulatory predicate for future technology advancements.

Autonomix Medical (AMIX) received a European patent for its neural activity assessment technology, expanding its intellectual property in autonomic nervous system assessment and neuromodulation. The patent covers systems to monitor and analyze neural activity in the eye, supporting patient assessment and treatment guidance. AMIX's technology is initially focused on pain treatment, with clinical trials targeting pancreatic cancer-related pain.

Autonomix Medical (AMIX) appointed Sandra Kalter, former Medtronic VP, to its board. Kalter brings 40+ years of medical tech, FDA regulatory, and transaction experience. She will advise on tech development, therapeutic applications, and industry partnerships. Autonomix is developing a nerve-sensing platform for cardiology, hypertension, and chronic pain management.

Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervat

Autonomix Medical (AMIX) will hold its annual meeting on October 29, 2026, to vote on a reverse stock split (ratio 1-for-2 to 1-for-25), expand its equity incentive plan, and elect directors. The company seeks approval for the board to implement the split within a year, which would reduce share count but maintain ownership percentages. AMIX had 1,828,505 shares outstanding as of September 8, 2026.

Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules THE WOODLANDS, TX, August 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedic